Get access

The impact of recent vincristine on human hematopoietic progenitor cell collection in pediatric patients with central nervous system tumors

Authors

  • Laura Cooling,

    Corresponding author
    1. Department of Pathology, University of Michigan, Ann Arbor, Michigan
    • Address reprint requests to: Laura Cooling, MD, MS, University of Michigan Hospitals, 2F225 UH-Blood Bank, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0054; e-mail: lcooling@med.umich.edu.

    Search for more papers by this author
  • Melissa Bombery,

    1. Department of Pathology, University of Michigan, Ann Arbor, Michigan
    Search for more papers by this author
  • Sandra Hoffmann,

    1. Department of Pathology, University of Michigan, Ann Arbor, Michigan
    Search for more papers by this author
  • Robertson Davenport,

    1. Department of Pathology, University of Michigan, Ann Arbor, Michigan
    Search for more papers by this author
  • Patricia Robertson,

    1. Department of Neurology, University of Michigan, Ann Arbor, Michigan
    2. Department of Pediatrics and Communicable Disease, University of Michigan, Ann Arbor, Michigan
    Search for more papers by this author
  • John E. Levine

    1. Department of Pediatrics and Communicable Disease, University of Michigan, Ann Arbor, Michigan
    2. Department of Bone Marrow Transplantation, University of Michigan, Ann Arbor, Michigan
    3. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
    Search for more papers by this author

Abstract

Background

Central nervous system (CNS) malignancies represent 20% of all childhood cancers. To improve outcomes in infants and children with high-risk disease, treatment can include adjuvant chemotherapy and early autologous peripheral blood human progenitor cell collection (AHPCC), followed by high-dose chemotherapy and stem cell rescue. In many protocols, postoperative chemotherapy includes the administration of weekly vincristine (VCR) between induction chemotherapy cycles, regardless of scheduled AHPCC. We observed anecdotal AHPCC failures in children receiving midcycle VCR (MC-VCR).

Study Design and Methods

The study was an 8-year retrospective chart review of all children with a CNS malignancy and who underwent AHPCC. Information included patient demographic and clinical data, mobilization regimen, VCR administration, product yields, infusion toxicity, and patient charges. Data were analyzed relative to MC-VCR administration. Graphics and statistical analysis (t-test, chi-square, linear regression) were performed with commercial software.

Results

Twenty-four patients and 47 AHPCCs were available for analysis. Nine patients (37%) received MC-VCR within 7 days of scheduled AHPCC. MC-VCR was associated with delayed marrow recovery (17.9 days vs. 14.9 days, p = 0.0012), decreased median peripheral CD34 counts (75 × 106 CD34/L vs. 352 × 106 CD34/L, p = 0.03), decreased median CD34 yields (2.4 × 106 CD34/L vs. 17.8 × 106 CD34/kg, p = 0.08), more AHPCCs per mobilization (2.9 vs. 1.1, p = 0.01), and an increased rate of remobilization (33% vs. 6%). Mean patient charges were 2.5× higher in patients receiving MC-VCR than controls (p = 0.01).

Conclusion

MC-VCR should be withheld before scheduled AHPCC to optimize CD34 collection.

Ancillary